An initiative to launch a regenerative medicine CDMO business that uses a cell culture center to undertake the manufacture of cell sheets for clinical use and investigational products for medical institutions, pharmaceutical companies and other customers, with the aim of progressing to technology disclosure agreements and revenue recognition.